[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 4, 2013

Progress With the Polypill?

Author Affiliations
  • 1VA Boston Healthcare System, Boston, Massachusetts
  • 2Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
  • 3Associate Editor, JAMA
JAMA. 2013;310(9):910-911. doi:10.1001/jama.2013.277066

The prevalence and disease burden of cardiovascular disease (CVD) and the widespread use of medications for its prevention and treatment have led to the concept that a single pill containing several cardiovascular medications, a “polypill,” might be useful in more effectively delivering pharmacologic interventions than the same medications prescribed and taken separately. For about a decade and a half there have been active discussions of combination pills for primary or secondary prevention of CVD.1 The discussion is consistent with the widespread interest in the importance of noncommunicable diseases, particularly in low- and middle-income countries.